polio vaccine

✓ Approved

Sanofi S.A · Vaccine · Vaccine

What is polio vaccine?

polio vaccine is a vaccine developed by Sanofi S.A. It is approved for therapeutic indications via unknown.

Drug Profile

Company	Sanofi S.A
Drug Class	Vaccine, Large Molecules
Route	Unknown
Status	Approved

Sources: ClinicalTrials.gov, Sanofi S.A

Therapeutic Indications

polio vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic Area	Condition	Phase
Surgical and medical procedures	Polio immunisation	✓ Approved

Related Research Articles

PubMedFrontiers in bioengineering and biotechnology2026-10-15

Effect of low-intensity blood flow restriction combined with high-intensity resistance training on lower limb strength and stroke effect of table tennis players.

Li Han H, Zhao Rui R, Xiao Yi Y

This study aimed to investigate the effects of different strength training protocols on lower limb strength and stroke effect in table tennis players. A single-blind randomized controlled trial (RCT) design was employed. A total of 30 table tennis players were recruited and randomly assigned into three groups: the low-intensity blood flow restriction training (LI-BFRT) group, high-intensity resistance training (HI-RT) group, and combined training (CB-RT) group. All participants completed an 8-week strength training intervention with three sessions per week. Key indicators including knee peak torque, squat jump (SJ) height, countermovement jump (CMJ) height, peak rate of force development (PRFD), and stroke effect were measured before and after the intervention. No significant differences in all baseline indicators were observed among the three groups (p > 0.05). After the intervention, the CB-RT group exhibited extremely significant improvements in knee flexion and extension peak torques, SJ and CMJ heights, PRFD, and stroke effect (p < 0.01). In the LI-BFRT group, left knee extension PT was extremely significantly improved (p < 0.01); Meanwhile SJ height, PRFD, and forehand topspin loop effect were all significantly enhanced (p < 0.05). In the HI-RT group, left knee extension PT was extremely significantly increased (p < 0.01); Meanwhile, left knee flexion PT, right knee flexion and extension peak torques, CMJ height, PRFD, and forehand backspin loop effect were all significantly improved (p < 0.05). The results indicate that compared with single LI-BFRT or HI-RT, CB-RT exhibited a greater improvement trend in lower limb strength and stroke effect among table tennis players.

PMID 42876602

Read full article →

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-10-15

Sub-Second Ratiometric Fluorescence Imaging of Histamine Dynamics in Living Cells via a Supramolecular Probe.

Chan Chenming C, Han Yujie Y, Song Yu-Fei YF, Jiang Chunlei C et al.

Histamine (HA) is a critical neurotransmitter, yet its intracellular dysregulation remains difficult to monitor due to the slow kinetics and environmental sensitivity of traditional fluorescent probes. Herein, we report a supramolecular ratiometric probe engineered via the host-guest self-assembly of cationic fluorophores with cucurbit[7]uril (CB[7]). By precisely modulating the cationic locus within the guests, we achieved a 2:1 (host:guest) stoichiometric complex (CB[7]2⊃GA-1) that displays a distinct 60 nm bathochromic shift. Functioning via a competitive displacement mechanism, this probe demonstrates exceptional selectivity and an ultrafast response time of 0.96 s (kobs = 3.56 s- 1). We successfully utilized this system to visualize real-time HA fluctuations in living mast cells with sub-second resolution. Notably, our imaging revealed a quantitative correlation between nigericin-induced cytoplasmic HA elevation and mast cell rupture. These findings validate the probe's efficacy in tracking cellular inflammatory responses and highlight its potential as an early-warning indicator for drug-induced cytotoxicity. Consequently, this work offers a robust tool for dissecting HA-related pathophysiology and establishes a generalizable design paradigm for the rapid, ratiometric sensing of biologically relevant analytes.

PMID 42875831

Read full article →

PubMedHaematologica2026-10-15

Cord blood-derived natural killer cells engineered with a novel, highaffinity chimeric antigen receptor can eliminate acute myeloid leukemia cells with minimal C-type lectin-like molecule-1 expression.

Suga Makiko M, Kida Shuhei S, Mizutani Yo Y, Kogue Yosuke Y et al.

CAR NK cell therapy is expected to be developed to treat acute myeloid leukemia (AML). C-type lectin-like molecule 1 (CLL-1) is a candidate target. However, AML cells with minimal CLL-1 expression (CLL-1dim) may not be eliminated by CAR NK cells. Here we demonstrate that cord blood (CB)-derived NK cells transduced with a novel high-affinity CAR that recognizes CLL-1 can eliminate CLL-1dim AML cells. A newly established anti- CLL-1 monoclonal antibody (mAb) designated as 2-23 exhibits a higher affinity for CLL- 1 than the widely used anti-CLL-1 mAb M26. CB-derived NK cells transduced with a CAR derived from 2-23, but not M26, killed CLL-1dim AML cells in vitro. Additionally, treatment with 2-23 CAR NK cells, but not M26 CAR NK cells, significantly enhanced the survival of the mice transplanted with CLL-1dim AML cells in vivo. Furthermore, in AML patient-derived xenograft models, the 2-23 CAR NK cells expanded robustly, persisted, and eradicated AML cells.

PMID 42876290

Read full article →

PubMedFrontiers in cellular and infection microbiology2026-10-15

Immunogenicity and protective efficacy of recombinant BCG expressing a multi-epitope vaccine against mycobacterium tuberculosis.

Zhang Xuan-Ji XJ, Luo Jia-Rui JR, Tian Ting-Ting TT, Shi Juan J et al.

Mycobacterium tuberculosis (Mtb) infects approximately one-quarter of the global population, of whom 5%-10% develop active tuberculosis (TB). Although Bacillus Calmette-Guérin (BCG) remains the cornerstone vaccine against severe infant TB, its efficacy in adults is limited, underscoring the need for novel TB vaccines. This study aimed to design a multi-epitope vaccine, tMEV, and validate its protective potential through bioinformatic prediction and in vivo experiments. tMEV was constructed from dominant T- and B-cell epitopes derived from Mtb ESAT-6, PE35, PPE38, and PE4 proteins, fused with an adjuvant. Its vaccine candidacy was assessed via physicochemical and solubility profiling, secondary and tertiary structure modeling, TLR-4 molecular docking, molecular dynamics simulation, and immune simulation. The tMEV coding sequence was cloned into pMV361 and transformed into BCG to generate recombinant BCG (rBCG-tMEV). Immunogenicity, antigenicity, and protective efficacy were evaluated in mouse immunization and Mtb challenge models. tMEV exhibited favorable vaccine-like properties in silico. In mice, both tMEV and rBCG-tMEV induced Mtb-specific immune responses. Compared with PBS, tMEV significantly enhanced cellular and humoral immunity with a Th2-biased profile. Relative to conventional BCG, rBCG-tMEV elicited a superior mixed Th1-Th2 response and higher antigen-specific immunity, accompanied by increased secretion of IFN-γ, IL-2, TNF-α, granzyme B, and perforin. Moreover, rBCG-tMEV markedly reduced bacterial loads in the lungs and spleens of Mtb-infected mice, conferring partial protection. These findings demonstrate that tMEV and rBCG-tMEV possess robust immunogenicity and protective potential against Mtb, representing promising novel TB vaccine candidates and providing a rationale for future vaccine development and optimization.

PMID 42876677

Read full article →

PubMedAdvanced materials (Deerfield Beach, Fla.)2026-10-15

Correction to "Screening Natural Cholesterol Analogs to Assemble Self-Adjuvant Lipid Nanoparticles for Antigens Tagging Guided Therapeutic Tumor Vaccine".

PMID 42876174

Read full article →

PubMedInfectious diseases and therapy2026-10-15

A Phase 1/2 Trial Evaluating the Safety and Immunogenicity of an mRNA-based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and Neuraminidase.

De Coster Ilse I, Cardona Jose F JF, Ferguson Murdo M, Leroux-Roels Isabel I et al.

Hemagglutinin (HA) is the principal immunologic target of most licensed seasonal influenza vaccines. Targeting both HA and neuraminidase (NA) might improve vaccine effectiveness. This randomized phase 1/2 study evaluated an investigational mRNA-based quadrivalent seasonal influenza vaccine, encoding HA and NA of A/H1N1, A/H3N2, B/Victoria, and B/Yamagata (FLUm4HA-4NA). In phase 1, adults aged 18-50 years received either one of twelve mRNA vaccine formulations of varying HA-only or HA and NA mRNA doses, or a licensed quadrivalent seasonal influenza comparator. In phase 2, participants aged 18-64 years (younger adults) and 65-85 years (older adults) received FLUm4HA-4NA (three groups per age category, with different HA/NA mRNA doses) or age-appropriate licensed quadrivalent comparator. Primary endpoints were safety/reactogenicity, and hemagglutination inhibition [HI] and NA inhibition [NI] responses against the four seasonal strains at day 29. Cross-reactive HI/NI responses against drifted strains, virus neutralization, and HA-/NA-specific cell-mediated immunity were evaluated in phase 2 as tertiary objectives. A total of 293 participants (21-25 per group) were vaccinated in phase 1, 480 younger (108-137 per group) and 483 older adults (117-125 per group) in phase 2. Solicited events were more frequent with FLUm4HA-4NA than comparators and were mostly short-lived and mild or moderate. No deaths or vaccine-related serious adverse events were reported. Post-vaccination HI and neutralizing titers in the FLUm4HA-4NA groups were similar or higher for the A strains and lower for the B strains versus comparators. NI responses exceeded those of comparators for all four strains. HI and NI titers against evaluated drifted A strains were similar or higher after FLUm4HA-4NA than after comparator vaccination. HA-specific CD4+ and CD8+ T-cell responses were generally higher after FLUm4HA-4NA than comparator vaccination. FLUm4HA-4NA showed an acceptable safety profile and humoral and cellular immunogenicity in the study population, supporting further development and formulation optimization to improve influenza B HI responses. ClinicalTrials.gov: NCT05823974; euclinicaltrials.eu: 2022-502308-66-00.

PMID 42875683

Read full article →

+9996 more articles available with a free account

polio vaccine

What is polio vaccine?

Drug Profile

Therapeutic Indications

Related Research Articles

Effect of low-intensity blood flow restriction combined with high-intensity resistance training on lower limb strength and stroke effect of table tennis players.

Sub-Second Ratiometric Fluorescence Imaging of Histamine Dynamics in Living Cells via a Supramolecular Probe.

Cord blood-derived natural killer cells engineered with a novel, highaffinity chimeric antigen receptor can eliminate acute myeloid leukemia cells with minimal C-type lectin-like molecule-1 expression.

Immunogenicity and protective efficacy of recombinant BCG expressing a multi-epitope vaccine against mycobacterium tuberculosis.

Correction to "Screening Natural Cholesterol Analogs to Assemble Self-Adjuvant Lipid Nanoparticles for Antigens Tagging Guided Therapeutic Tumor Vaccine".

A Phase 1/2 Trial Evaluating the Safety and Immunogenicity of an mRNA-based Seasonal Influenza Vaccine Candidate Encoding Hemagglutinin and Neuraminidase.

Ask about polio vaccine